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OBJECTIVES: Several cytokines secreted from breast cancer tissues are suggested to be related to disease
prognosis. We examined Th1/Th2/Th17 cytokines produced from three-dimensionally cultured breast cancer
tissues and related them with patient clinical profiles.METHODS: 21 tumor tissues and 9 normal tissues surgically
resected from breast cancer patients were cultured in thermoreversible gelatin polymer–containing medium.
Tissue growth and Th1/Th2/Th17 cytokine concentrations in the culture medium were analyzed and were related
with hormone receptor expressions and patient clinical profiles. RESULTS: IL-6 and IL-10 were expressed highly in
culture medium of both cancer and normal tissues. However, IFN-γ, TNF-α, IL-2, and IL-17A were not detected in
the supernatant of the three-dimensionally cultured normal mammary gland and are seemed to be specific to
breast cancer tissues. The growth abilities of hormone receptor–negative cancer tissues were significantly higher
than those of receptor-positive tissues (P = 0.0383). Cancer tissues of stage ≥ IIB patients expressed significantly
higher TNF-α levels as compared with those of patients with stage b IIB (P = 0.0096). CONCLUSIONS: The tumor
tissues resected from breast cancer patients can grow in the three-dimensional thermoreversible gelatin polymer
culture system and produce Th1/Th2/Th17 cytokines. Hormone receptor–positive cancer tissues showed less
growth ability. TNF-α is suggested to be a biomarker for the cancer stage.
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Individualized pharmacotherapeutic approaches in breast cancer
patients have been carried out according to the histological findings
of tumors and the difference of the stages. Hormone receptors and
HER2 could be efficient targets for the individualized breast cancer
pharmacotherapy. However, in case of the patients negative with
these targets, the effectiveness of cytotoxic chemotherapy largely
influences the patient outcome.
Many kinds of immune cells are known to work to exclude cancer
cells [1], whereas it has been suggested that the cancer cells secrete
cytokines to escape from the tumor immunity [2]. The cytokine
network made by cancer cells contributes to growth and development
of tumors and inhibits host immunity [3] by disturbing theeffector-cell responses [4]. Th2 cytokines are reported to increase in
tumor tissues, which can act to suppress tumor immunity [5]. Indeed,
many kinds of cytokines [6], such as IL-6, IL-8, and IL-10 [7,8], have
been reported to be upregulated in tumor tissues. Moreover, increase
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disease stage and progression of cancer [9]. Thus, it is suggested
that cytokines play important roles in the pathology or prognosis
of cancer.
Many types of gels have been used for three-dimensional culture of
mammalian cells and tissues, which include spinner cultivation
technique [10], alginate beans [11], agarose [12], soft agarose,
Matrigel [13], or collagen matrix gel [14]. However, cytotoxic
enzyme use is required for culturing the cells or tissues in these culture
systems. The three-dimensional culture system using thermoreversi-
ble gelatin polymer (TGP) [15] is simple and easy for culturing cells
or tissues and collecting culture superatant without effecting damages
on the cells. TGP is a heat-reversible hydrogel constituted by block
copolymer of hydrophilic polymer and temperature-sensitive poly-
mer. TGP has a unique property as a gel in high temperature and a
sol state in low temperature reversibly, with a transition temperature
of 22°C. The cell toxicity of TGP is extremely low so that cells can
be cultured for long time in this gel system. Moreover, fibroblasts
are hard to grow, whereas cancer cells can easily proliferate, in the
TGP gel.
In this study, we three-dimensionally cultured breast cancer and
normal mammary tissues, surgically resected from patients, by using
TGP and investigated the growth ability of the tissues or Th1/Th2/
Th17 cytokines secreted from the tissues. These biomarkers are also
related with patient clinical profiles, including the hormone receptors
and the stage of tumor.
Materials and Methods
Patients’ Characteristics
This study was approved as "The study for cytokines secreted from
breast cancer tissues" by the Ethics Committee of the Cancer Institute
Hospital of JFCR in June 2012, and informed consent was obtained
from all the patients before enrolling participants in this study. We
evaluated a total of 21 patients diagnosed as having breast cancer in
the Department of Breast Cancer Oncology of The Cancer InstituteTable 1. Patient Characteristics
Case Number Age Chemotherapy Menopause ER PR
Case 1 57 − Post − −
Case 2 42 − Pre − −
Case 3 41 + Pre − −
Case 4 61 − Post + −
Case 5 43 − Pre + +
Case 6 48 − Pre + +
Case 7 74 + Post − −
Case 8 46 + Pre + +
Case 9 34 − Pre − −
Case 10 51 + Pre + −
Case 11 64 + Post + +
Case 12 43 + Pre − −
Case 13 62 + Post + −
Case 14 67 + Post + +
Case 15 47 + Pre + +
Case 16 62 + Post + +
Case 17 45 + Pre + +
Case 18 48 + Pre + +
Case 19 59 + Post − −
Case 20 57 + Post + +
Case 21 81 + Post − −
Twenty-one breast cancer patients were included. ER, PgR, and HER2 in cancer tissue were detected
performed. Nuclear grade (NG) and tissue type were performed by pathologic examination.Hospital of JFCR (all of them are women, and their mean age was
53.9 years) (Table 1). Paclitaxel, docetaxel, herceptin, cyclophospha-
mide/epirubicin/5-FU, docetaxel/adriamycin/cyclophosphamide,
and cyclophosphamide/adriamycin/5-FU were used as adjuvant
chemotherapy in 6 out of 21 patients. Statuses for estrogen receptor
(ER), progesterone receptor (PgR), and HER2 in cancer tissues were
examined by immunohistochemical analysis. The breast cancer tissues
were surgically resected from these patients for the purpose of their
therapy, and 12 tissues resected from 12 patients out of the 21
patients were cultured in The Cancer Institute Hospital, whereas the
other 9 tissues from 9 patients were cultured in Tokyo University of
Pharmacy and Life Sciences. The nine normal mammary tissues from
the latter nine patients were also provided and cultured, and eight of
them were used for cytokine measurement.
Three-Dimensional Culture of Resected Tissues
Breast cancer tissues and normal mammary tissues were obtained
by surgery or biopsy from 21 patients. The tumor size in all of
the patients was more than 3 cm at their diagnosis. Each tissue
was immersed in a tissue carry solution, Hanks’ Balanced Salt
Solution (Sigma-Aldrich, USA), including penicillin, streptomycin,
and amphotericin B. The tissues were washed by the solution
more than three times to prevent bacterial infection. After removal
of blood and fat, the tissues were cut into pieces to sizes less than
0.5 mm3. Two to three pieces of the tissue were seeded in a well
of DSeA-3D Plate (IFTL Inc., JAPAN) filled with TGP (IFTL
Inc.). After incubating in 5% CO2 for 30 minutes at 37°C,
325 μl/well of RPMI1640 including 16% FBS (SAFC Biosciences,
Inc., USA) was added, and the plate was warmed to 37°C.
Then, 25 μl/well of PBS (GIBCO Inc., USA) was added, and the
plate was incubated in 5% CO2 at 37°C for 6 days. After the
incubation, 250 μl/well of the supernatant was collected and stored at
−80°C. Under the same condition, a blank well that included no
tissue was prepared. The supernatant after 6 days of incubation was
collected in the same manner. All of these experiments were carried
out axenically.HER2 FISH NG Tissue Type Stage
3+ Unknown 1 a3 Unknown
0 Unknown Unknown a3 IIIC
1+ Unknown 3 a2 IIA
2+ − 2 a2 IIIC
0 Unknown Unknown a3 IIIC
0 Unknown 2 a3 IIIA
0 Unknown 3 a2 IIA
0 Unknown 1 a3 IIA
0 Unknown Unknown a3 IV
1+ Unknown 1 a3 IIA
0 Unknown 3 a3 IIA
1+ Unknown 3 a2 IIA
1+ Unknown 1 a3 IIA
2+ − 3 a2 IIA
2+ + 2 a3 IIA
0 Unknown 2 a3 IIA
0 Unknown 2 a1 IIA
1+ Unknown 2 a3 IIA
1+ Unknown 3 a3 IIA
0 Unknown 2 a3 IIA
2+ − 2 a3 IV
by immunohistochemical analysis. In the case for HER2 2+, fluorescence in situ hybridization was
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A total of 25 μl/well Cell Counting Kit-8 reagent (DOJINDO
Inc., Japan) was added to each well of DSeA-3D plate after
incubation of each tissue for 6 days at 37°C under 5% CO2. After
incubation in 5% CO2 at 37°C for 2 hours, the absorbance at 450 nm
in each well was measured using the microplate reader SAFIRE
(TECAN Inc., JAPAN). The data subtracted from the value of blank
well from each sample well were calculated.
Th1/Th2/Th17 Cytokine Measurements
The supernatant of three-dimensionally cultured breast cancer
tissue and normal mammary tissue as prepared above was diluted four
times with Wash Buffer (BD Inc., USA). The Wash Buffer was
filtrated by 0.2μmmembrane before use. Then, the concentrations of
seven cytokines, IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, and
IL-17A, in the supernatant were measured using BD Cytometric
Beads Array (CBA) Human Th1/Th2/Th17 Cytokine Kit (BD Inc.,
USA), followed by flow cytometry. The detection limits for these
cytokines were 2.6, 4.9, 2.4, 4.5, 3.8, 3.7, and 18.9 pg/ml for IL-2,
IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17A, respectively. The
concentration of each cytokine less than the detection limits was
recognized as 0 pg/ml. These procedures followed the manufacturer’s
instruction, and the data were analyzed with BD CBA software.
Statistical Analysis
Statistical significances for the difference of the WST-8 assay values
and the concentrations of cytokines in the culture supernatant between
the three-dimensionally cultured breast cancer tissues and the normal
mammary tissues were analyzed using Wilcoxon signed rank test. The
χ2 test was performed for analyzing differences in the frequencies of IL-6
and IL-10 expression between normal and cancer tissue cultures. The
Mann-WhitneyU test was used to compare the cytokine concentrations
between patient subgroups that underwent chemotherapy and those
without chemotherapy. The correlations between the WST-8 assay
values of cancer or normal mammary tissues and the concentrations of
each cytokine in the supernatant were analyzed by the Spearman or
Pearson correlation coefficient. Statistical significances for the differ-
ences of the WST-8 assay values and the concentrations of seven
cytokines between patients with ER positive (ER+) and those with ER
negative (ER−) cancer tissues were analyzed by Mann-WhitneyU test.
χ2 tests were performed for analyzing differences in the frequencies of
patients with cancer tissues exhibiting relatively higher WST-8 assay
values or concentrations of seven cytokines produced into culture
medium between ER+ and ER− patients. Statistical significance for the
differences of the WST-8 assay values or the concentrations of seven
cytokines between patients with PgR positive (PgR+) and those with
negative (PgR−) tissues was analyzed by unpaired t test with Welch
correction. χ2 tests were performed for analyzing differences in the
frequencies of patients with cancer tissues exhibiting relatively higher
WST-8 assay values or concentrations of seven cytokines produced into
culture medium between PgR+ and PgR− patients. Mann-Whitney
U test was used to compare concentrations of each cytokine in culture
mediumbetween patients with stage IIA and those with stages later than
IIB. χ2 tests were used to analyze differences in the frequencies of
patients with cancer tissues exhibiting relatively higher concentrations
of seven cytokines in culture medium between patients with stage IIA
and those with stages later than IIB. P values less than 0.05 were
estimated to be statistically significant. All statistical analyses were
carried out byGraphPadPRISM4.0 (GraphPrismSoftware Inc., USA).Results
Growth Ability of Three-Dimensionally Cultured Breast
Cancer Tissues and Normal Mammary Tissues
Growth abilities of three-dimensionally cultured breast cancer
tissues (n = 21) and normal mammary tissues (n = 9) were analyzed
by WST assay. Whereas cancer tissues tended to show higher growth
potential than normal tissues, there was no significant difference (P =
0.3125) (Figure 1A). Growth abilities of breast cancer tissues resected
from patients under chemotherapy (n = 6) seemed to be higher than
those from the patients without chemotherapy (n = 15), but there
was no significant difference (P = 0.1291) (Figure 1B).
Characterization of Th1/Th2/Th17 Cytokines in Supernatant
of Three-Dimensionally Cultured Tissues
We measured the concentrations of IFN-γ, TNF-α, IL-2, IL-4,
IL-6, IL-10, and IL-17A secreted in the supernatant of three-
dimensionally cultured breast cancer tissues (n = 21) and normal
mammary tissues (n = 8). Both of the cancer and the normal
mammary tissues secreted IL-6 and IL-10 in the supernatant
(Figure 2). However, IFN-γ, TNF-α, IL-2, and IL-17A were only
detected in the supernatant of cancer tissues (Figure 2). IL-4 was not
detected in each culture supernatant (Figure 2). There were no
significant differences in IL-6 and IL-10 concentrations between
cancer and normal tissues. The frequency for the excretion of IFN-γ
into the culture supernatant of breast cancer tissues was statistically
higher than that of the normal mammary tissues (P = 0.0052)
(Table 2). Thus, IFN-γ is considered to be specific to cancer tissues.
The concentrations of IFN-γ and IL-10 in the supernatant of
cancer tissues obtained from the patients who underwent chemo-
therapy (n = 6) tended to be higher than those in the supernatant of
cancer tissues obtained from the patients without chemotherapy (n =
15), although the differences were not statistically significant
(Figure 3). There was no difference in IFN-γ, TNF-α, IL-2, IL-6,
IL-10, and IL-17A concentrations between these patient
subgroups (Figure 3).
The growth abilities of cancer tissues as assessed by WST-8 assay
significantly correlated positively with concentrations of IFN-γ (A;
P = 0.0031 by Pearson), IL-6 (D; P = 0.0274 by Pearson and P =
0.0009 by Spearman), and IL-10 (E; P = 0.0158 by Pearson and P =
0.0003 by Spearman), whereas those of TNF-α (B), IL-2 (C), and
IL-17A (F) did not (Figure 4). The growth abilities of normal
mammary tissues were significantly correlated positively with
concentrations of IL-10 (P = 0.0458) (Figure 5B); however, there
was no significant correlation between normal tissue growth and IL-6
concentration (Figure 5A).
Relationship between Growth Abilities or Cytokine Amounts in
Cultured Tissues and Female Hormone Receptor Expression
We investigated differences of the growth abilities of cancer tissues
as assessed by WST-8 assay or seven cytokine concentrations in
supernatant of three-dimensionally cultured cancer tissues, between
ER+ and ER−, PgR+ and PgR−, or HER2+ and HER2− tissues,
respectively. There were no significant differences in IFN-γ, TNF-α,
IL-2, IL-4, IL-6, IL-10, and IL-17A concentrations between the ER+
and ER−, PgR+ and PgR−, or HER2+ and HER2− tissues (n = 21)
(data not shown). On the other hand, there was a significant
difference in the WST-8 assay values of breast cancer tissues between
the PgR+ and the PgR− patient subgroups (P = 0.0383) (Figure 6B),
whereas the WST-8 assay values were not significantly different
Figure 1. Growth abilities of three-dimensionally cultured breast cancer tissues. The growth abilities of the tissues three-dimensionally
cultured in TGP gel were assessed byWST-8 assay (absorbance at 450 nm; see Materials and Methods) after the culture. (A) Comparison
of the growth abilities between breast cancer tissues (n = 21) and normal breast tissues (n = 9). No significant difference was observed
as analyzed by Wilcoxon signed rank test (P = 0.3125). (B) Comparison between cancer tissues from patients treated by chemotherapy
(n = 6) and those from patients who were not treated by chemotherapy (n = 15). No significant difference was observed as analyzed by
Mann-Whitney test (P = 0.1291).
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(Figure 6A). Then, 21 breast cancer tissues were grouped into the
high– or low–growth ability subgroup by the median of the WST-8
values (0.3026 read by absorbance at 450 nm), and the frequencies
for the hormone receptor expression in cancer tissues were compared.
The ER− tissues showed significantly higher incidence of the
high-WST-8 value than the ER+ tissues by χ2 test (P = 0.0306),
whereas there was no significant difference in the incidence of the
high-WST-8 value between the PgR+ and the PgR− tissues (P =
0.0502) (Table 3).
Relationship between Stages of Cancer and Growth Activities or
Cytokine Concentrations in Supernatant in Three-Dimensionally
Cultured Cancer Tissues
All patients were divided into the IIA-stage group (n = 14) and the
IIB-or-later-stage group (n = 6), and the WST-8 assay values of theND ND NDND DNDN
Figure 2. Comparison of cytokine concentrations in supernatant of
three-dimensionally cultured breast cancer and normal tissues.
Breast cancer tissues (cancer tissues) or normal tissues of breast
cancer patients (normal tissues) were cultured for 6 days in TGP
gel, respectively, and the cytokine concentrations in supernatant
were determined by CBA assay procedures. Twenty-one cancer
tissues and eight normal tissues were examined. The mean ± SD
concentrations were indicated. The cytokine concentrations did
not significantly differ between cancer tissues and normal tissues.
The frequencies of the expression of IFN-γ were significantly
different between the cancer tissues and the normal tissues as
analyzed by χ2 test (P = 0.0052). ND (not detected): The cytokine
concentrations were under each detection limit.cultured tissues or the concentrations of IFN-γ, TNF-α, IL-2, IL-4,
IL-6, IL-10, and IL-17A in supernatant were compared. There were
no significant differences in the cytokine concentrations and the
WST-8 values between the two stage groups (data not shown). We
also compared the incidence of each cytokine secretion between the
stages. Eight out of 21 cancer tissues secreted TNF-α into the culture
supernatant. The cancer tissues obtained from the patients with stages
IIB or later showed significantly high incidence of TNF-α secretion as
compared with the tissues obtained from the stage IIA patients (P =
0.0096) (Table 4).
Discussion
We showed in this study that tumor tissues, as well as normal
mammary tissues, resected from breast cancer patients are able to
grow in a three-dimensional culture system using TGP and produce
several kinds of cytokines into the culture medium.
Cancer tissues tended to grow more than normal mammary tissues,
but there was no significant difference. There are generally significant
growth differences found between normal and cancer cells. In the
present study, we used TGP culture system, in which cells other thanTable 2.Differences for the Incidence of Each Cytokine Expression between Breast Cancer Tissues
and Normal Tissues
Cytokine Cutoff Value (pg/mL) Expression Cancer Normal Total P Value
IFN-γ (3.7) + 12* 0 12 *P = 0.0052
− 9 8 17
TNF-α (3.8) + 6 0 6 P = 0.0896
− 15 8 23
IL-2 (2.6) + 7 0 7 P = 0.0608
− 14 8 22
IL-4 (4.9) + 0 0 0 Not analyzed
− 21 8 29
IL-6 (2.4) + 19 6 25 P = 0.2800
− 2 2 4
IL-10 (4.5) + 16 4 20 P = 0.1730
− 5 4 9
IL-17A (18.9) + 2 0 2 P = 0.3657
− 19 8 27
The resected tissue samples were grouped into those expressing and not expressing each cytokine,
and the difference for the incidence of cytokine production between cancer and normal tissues was
analyzed. The cutoff points of cytokine expressions were the detection limit of each cytokine
concentration shown in the table. Statistical analysis was performed by χ2 test. The incidence for the
expression of IFN-γ was significantly higher in cancer tissues (*P = 0.0052).
Figure 3. Comparison of each cytokine concentration in supernatant of three-dimensionally cultured tissues obtained from patients with
and without chemotherapy. IFN-γ, TNF-α, IL-2, IL-6, IL-10, and IL-17A in the supernatant of three-dimensionally cultured tissues obtained
from patients with (n = 6) or without (n = 15) chemotherapy were compared. There was no difference in IFN-γ (A; P = 0.0662), TNF-α (B;
P = 0.1612), IL-2 (C; P = 0.4254), IL-6 (D; P = 0.1106), IL-10 (E; P = 0.0674), and IL-17A (F; P = 0.7086) concentrations between these
patient subgroups, as analyzed by Mann-Whitney U test.
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clinically resected tissue samples obtained from cancer patients, which
is another difference from the culture system of the previous
researchers using cell lines. Thus, the growth of clinically resected
tissues in TGP gel is suggested to be relatively slow as compared with
the growth of cells derived from cancer cell lines in other
three-dimensional culture system. It may also be considered that
the small sample size for normal tissues in the present study
influenced the statistical analysis power. These points in combination
are suggested to be implicated in the controversial observation
between our present data and those of other researchers.
Chemotherapy did not influence significantly the in vitro growth
of cancer tissues after surgical resection in this three-dimensional
culture system. The production of IFN-γ, TNF-α, IL-2, IL-10, and
IL-17 from the three-dimensionally cultured tissues into medium
appeared to be greater in cancer tissues obtained from the patients
under chemotherapy than those from the patients without
chemotherapy, but the differences were not statistically significant.
In the study “Breast Invasive Carcinoma” in the public domain The
Cancer Genome Atlas, the patients administered adjuvant postoper-
ative pharmaceutical therapy indicator express higher IFN-γ mRNA
than those without the therapy [16]. Hormone positive cancer tissues
showed significantly less ability to grow in this culture system. IFN-γ,
TNF-α, and IL-2 are likely to be specific to cancer tissue, and TNF-α
is suggested to be a biomarker for the stage of breast cancer.
The three-dimensionally cultured breast cancer tissues secreted
markedly high amounts of IL-6 and IL-10. IL-6 has been suggested to
have multifaceted action to breast cancer cells in vitro. There is
another report that suggests that IL-6 is a growth factor of
three-dimensionally cultured ER(+) breast cancer cells in vitro andin vivo [17]. It has been reported that there was no significant
difference in the distribution of the IL-6 572G/C polymorphisms
between lung cancer patients and healthy controls [18]. From these
observations of other researchers, some of DNA encoding IL-6 and
IL-10 might be expressed in both cancer and normal tissues.
Cancer tissue consists of various phenotypes, and some of them are
cancer stem cells, which have oncogenicity and accelerate tumor
progression [19]. Cancer stem cells have the ability to grow as sphere,
called mammosphere. IL-6 has been reported to control the balance
of reversible change between cancer stem cells and noncancer stem
cells [20]. Cancer stem cells are known to produce a larger amount of
IL-6 as compared with noncancer stem cells [20]. Breast cancer is
suggested to be one of the stem cell diseases [21], and the growth of
cancer depends on the growth of cancer stem cells and the ability of
self-renewal [22–24]. It has been reported that, in human carcinoma
or mammosphere derived from normal mammary gland, IL-6 induces
malignant progression [25]. In our study, we observed high
concentrations of IL-6 in the supernatant of three-dimensionally
cultured normal mammary tissues as well as those of breast cancer
tissues, suggesting that malignant progression is induced in normal
mammary tissue.
In the present study, IL-10 was detected almost equally in cancer
and normal tissues. It may be explained that IL-10 secreted from
cancer tissue plays a role as the growth activator, whereas IL-10
secreted from normal mammary gland may act as the growth
inhibitor. Recent findings suggest that regulatory B (Breg) cells
inhibit autoimmune diseases [26]. Breg cells have been reported to
produce IL-10 [27]. Breg cells are known to be induced from B cells
of primary breast cancer patients [28]. Hence, it may be possible to
consider that the three-dimensionally cultured breast cancer tissues
Figure 4. Correlation between cytokine concentrations in supernatant of three-dimensionally cultured breast cancer tissues and WST-8
assay values of the cultured tissues. The growth abilities of the tissues three-dimensionally cultured in TGP gel were assessed by WST-8
assay (absorbance at 450 nm) after the culture. Correlations were evaluated by Pearson correlation coefficient test and Spearman
correlation coefficient test (n = 21). Concentrations for IFN-γ (A; P = 0.0031 by Pearson), IL-6 (D; P = 0.0274 by Pearson and P = 0.0009
by Spearman), and IL-10 (E; P = 0.0158 by Pearson and P = 0.0003 by Spearman) in the culture supernatant were significantly correlated
with the growth abilities of the tissues as evaluated by the WST-8 assay, whereas those of TNF-α (B), IL-2 (C), and IL-17A (F) were not.
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of view, further study is needed to define from where each cytokine
was produced.
In this study, IL-17A was also detected with high concentration in
the supernatant of three-dimensionally cultured breast cancer tissues,
whereas it was not detected in normal tissue. IL-17 is produced from
various T-cell subsets such as CD4+ T cells, CD8+ T cells, NKT cells,Figure 5. Correlation between cytokine concentrations in supernata
assay values of cultured tissues. Correlation was evaluated by Pearso
test (n = 8). Concentrations for IL-10 (B) in the culture supernatant wa
(P = 0.0458 by Spearman); however, there was no significant correland γδT cells [29–32]. Cancer tissues are suggested to express IL-17
[33,34], and IL-17 promotes cancer angiogenesis resulting in cancer
advance [35].
Th2 cytokines produced in cancer microenvironment are suggested
to play a role in inhibition of cellular immunity against cancer [36].
Th1 cytokines were lower, whereas Th2 cytokines were higher, in
gastric cancer patients who have lymph node metastasis [37]. In thent of three-dimensionally cultured normal tissues and the WST-8
n correlation coefficient test and Spearman correlation coefficient
s significantly correlated with theWST-8 assay values of the tissues
ation between normal tissue growth and IL-6 concentration (A).
BA
*
Figure 6. Comparison for the WST-8 assay values of three-dimensionally cultured tissues between hormone receptor–positive and
–negative breast cancer tissues. (A) Comparison between ER(+) tissues (n = 13) and ER(−) tissues (n = 8). (B) Comparison between
PgR(+) tissues (n = 10) and PgR(−) tissues (n = 11). A significant difference for the WST-8 indices was observed between PgR(+) and
PgR(−) tissues as analyzed by unpaired t test with Welch correction (P = 0.0383).
Table 4. Relationship between the TNM Stages and the Incidences of Cytokine Production in
Culture Medium of Three-Dimensionally Cultured Breast Cancer Tissues
The Incidence of Cyto-
kine in Cultured Cancer
Tissue
TNM Stage P Value
Stage IIA Over Stage IIB Total
IFN-γ Positive 7 4 11 P N 0.05
Negative 7 2 9
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tissues contain high amounts of Th2 cytokines such as IL-6 and IL-10
rather than Th1 cytokines such as IFN-γ and TNF-α. These results
are consistent with other observations described above. IL-6 and
IL-10 were detected in the supernatant of both cancer and normal
tissues, whereas others were not detected in normal tissues.
The production of IFN-γ, TNF-α, IL-2, IL-6, IL-10, and IL-17A
in cancer patients treated by chemotherapy tended to increase
compared with the patients without chemotherapy (Figure 3).
Especially, there was a big difference between absolute IL-17A
concentrations. There was a report describing that IL-17–mediated
paracrine network promotes resistance of cancer tissues to antiangio-
genic therapy [38]. IL-17 is also known to promote tumor resistance
to VEGF inhibitory therapy [39]. In general, inflammation is
initiated by chemotherapeutic drug. High concentrations of IL-1β
and IL-6 were observed in patients with poor response speed
performance and were perceived cognitive disturbances [40]. From
the viewpoint stated above, it is considered that the breast cancer
tissues from the patients with chemotherapy may secrete several
cytokines, which make the tumor to be resistant to chemotherapy.
It is known that IL-6 promotes the growth of breast cancer cells
[41], and thus, it can be considered that the IL-6 secreted from breast
cancer tissue promotes through an autocrine mechanism. Whereas
IL-10 inhibits Th1 immunity and it may conversely promote
proliferation of cancer potentially, it also inhibits cancer growthTable 3. Relationship between ER or PgR Expression Incidence and theWST-8 Assay Value (Index
for Tumor Growth) of Three-Dimensionally Cultured Breast Cancer Tissues
WST-8 Assay Value for 3D Cultured Sample
Higher Lower Total
ER + 5 8 13
− 6* 2 8
Total 11 10 21
PgR + 3 7 10
− 8 3 11
Total 11 10 21
The patients were grouped into the higher and lower subjects expressing higher and lower WST-8
assay values, respectively, by the median score (0.3026 read by absorbance at 450 nm) for the results
of WST-8 assay of 3D cultured sample. On the other hand, the patients were divided into the ER
positive (+) and ER negative (−) or PgR positive (+) and PgR negative (−) groups. ER and PgR of
patients’ cancer tissue were detected by immunohistochemical analysis. Statistical analysis for the
incidence of subjects with cancer tissues exhibiting the high WST-8 values in vitro was performed
by χ2 test. The ER(−) tissues exhibited a significantly high incidence of the greater WST-8
assay-values (*P = 0.0306).indirectly through antiangiogenic mechanism [42]. IL-10 is known as
not only immunosuppressive but also inducible of inflammation, and
it augments cytotoxic activity and growth of CD8+ T cells [43]. In
this study, concentrations of IFN-γ, IL-6, and IL-10 in the
supernatant of three-dimensionally cultured breast cancer tissues
correlated positively with the growth of the tissues, as analyzed by
WST-8 assay. Serum concentrations of IFN-γ, IL-2, IL-6, and
granulocyte-macrophage colony-stimulating factor have been report-
ed to increase, whereas serum concentrations of IL-1 and TNF-α
decrease, in cancer patients treated by docetaxel or paclitaxel [44]. In
our study, only 3 out of 21 patients examined were treated by taxane
before extirpation of cancer tissue sample, and thus, the effect of
taxane on serum cytokine concentration has not been clarified.
The role of IL-17 in cancer starts from the initial stages of
tumorigenesis having already been established as having a role in the
earliest formation of a tumor by its increased presence within the
tumor microenvironment [45]. It has been demonstrated that IL-17–TNF-α Positive 3 5 * 8 *P = 0.0096
Negative 11 1 12
IL-2 Positive 4 3 7 P N 0.05
Negative 10 3 13
IL-4 Positive 0 0 0 Not analyzed
Negative 14 6 20
IL-6 Positive 5 5 10 P = 0.051
Negative 9 1 10
IL-10 Positive 10 5 15 P N 0.05
Negative 4 1 5
IL-17A Positive 1 1 2 P N 0.05
Negative 13 5 18
Total 14 6 20
The patients were divided into positive and negative groups for the cytokine production in culture
medium of three-dimensionally cultured breast cancer tissues. The cutoff limits of cytokine
expressions were the median of each cytokine concentration (all median was 0 pg/ml).
On the other hand, the patients were divided into the stage-IIA and over-stage-IIB groups. Then,
the statistical analysis was performed by χ2 test for the incidence of cytokine production from
their three-dimensionally cultured cancer tissues into culture medium. The patients with stages over IIB
of TNM stage exhibited significantly higher incidence for the TNF-α production in their three-dimension-
ally cultured tissues.
* P = .0096.
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induced from naive CD4+ and CD8+ T cells in the presence of
TGF-β and IL-6, which are highly produced in the tumor
microenvironment [46,47]. In our result, it is possible to consider
that IL-17–producing cells such as Tc17 cells induced by Th1
cytokines secreted by surrounding cancer tissues produce IL-17.
Finally, we demonstrated that the WST-8 assay values of
three-dimensionally cultured human breast cancer tissues have
relationships with cytokine concentrations in supernatant, stages of
patients, and clinical data. We observed that the ER− cancer tissues
exhibited significantly high incidence of greater growth ability in the
absence of ER than that of ER+ tissues (Table 3). In the study “Breast
Invasive Carcinoma” in The Cancer Genome Atlas, TNFAIP3 gene,
which strongly inhibits NFκB signaling, and ESR1 gene encoding ER
have significant tendency towards co-occurrence (P = 0.027, log odds
ratio: 0.931) [16]. It means that NFκB signaling is inhibited by
TNFAIP3 expression in breast cancer patients expressing ESR1.
Growth of ER+ breast tumor is well known to be promoted by
estradiol, and therefore the patients with ER+ breast tumor are
sensitive to endocrine therapy such as antiestrogen, aromatase
inhibitor, or LH-RH analog. The expression of PgR has been
reported to influence the therapeutic effect of tamoxifen significantly
[48]. In a retrospective cohort study dealing with more than 14,000
breast cancer patients, the survival rate in ER+/PgR− or ER−/PgR−
patients decreased as compared with that in ER+/PgR+ patients [49].
The tumor-proliferative indices, WST-8 assay values, of hormone
receptor–negative breast cancer tissues were significantly higher than
those of hormone receptor–positive tissues; the proliferation of
positive one is higher than negative one (Table 3). These observations
suggest that the hormone receptor–negative breast cancer tissues can
progressively grow in our culture system, which may be related to
their malignancy. On the other hand, the ER-positive cancer tissues
could not extensively grow without estrogen in the present TGP
culture conditions.
In our result, the higher the stage of cancer was, the more the
cancer tissues frequently secrete TNF-α into supernatant of
three-dimensional culture (Table 4). TNF-α serum concentration
was significantly higher in colorectal cancer patients than in controls.
The highest TNF-α level was found in stage IV patients and was
significantly elevated as compared with patients in earlier stages of
colorectal cancer and controls. The survival rate of colorectal patients
with low TNF-α serum concentration was significantly higher than
that of patients with high levels of TNF-α [50]. It is also reported that
plasma TNF-α concentrations were significantly elevated in benign
and malignant breast masses than healthy controls and were also
higher in malignant masses than in benign breast masses [51]. Thus,
our results that the tissues of advanced breast cancer frequently secrete
TNF-α did not conflict with the observations of these reports.
Our present study, in conclusion, showed that the three-dimensionally
cultured human breast cancer tissues using TGP secreted relatively
high amounts of Th2 cytokines such as IL-6 and IL-10 into the
culture medium. These cytokines possibly suppress tumor immunity
related to Th1 cell immunity and promote the proliferation of
cancer. IFN-γ, TNF-α, IL-2, and IL-17A were not detected in the
supernatant of the three-dimensionally cultured normal mammary
gland and seemed to be specific to breast cancer tissues.
Hormone-positive cancer tissues showed less ability to grow in this
culture system. TNF-α is suggested to be a biomarker for the stage of
breast cancer.Conflict of Interest
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